Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Compañía farmacéutica francesa busca proyectos para resolver la fase de inflamación de enfermedades autoinmunes o inmunoinflamatorias crónicas

Resumen

Tipo:
Demanda Tecnológica
Referencia:
TRFR20180615001
Publicado:
17/07/2018
Caducidad:
18/07/2019
Resumen:
Una compañía farmacéutica francesa está interesada en ampliar su catálogo con candidatos de fase temprana, preclínica o clínica en el campo de enfermedades autoinmunes e inmunoinflamatorias. La empresa busca socios industriales o académicos para participar en proyectos de desarrollo conjunto, licencia o compra de activos y está especialmente interesada en enfermedades como lupus, síndrome de Sjögren y esclerosis sistémica, aunque también en otras enfermedades autoinmunes o inflamatorias crónicas. El objetivo es establecer una cooperación a largo plazo con apoyo financiero.

Details

Tittle:
A French pharmaceutical company is looking for projects targeting the resolution of inflammation phase in autoimmune or chronic immuno-inflammatory diseases
Summary:
A French pharmaceutical company is interested to enrich its portfolio with early stage as well as preclinical or clinical candidates on autoimmune and immuno-inflammatory diseases. The company desires to engage in joint development, in-licensing or asset purchase partnerships and is primary interested by diseases such as Lupus, Primary Sjögren´s syndrome and Systemic Sclerosis, and also by other autoimmune or chronic inflammatory diseases.
Description:
This French international and independent pharmaceutical company, governed by a non-profit foundation, is focused on developing new therapies for unmet medical needs.As the 2nd French pharmaceutical company and the 30th worldwide, with 3 research centers and 16 production sites this French company has a global reach. With 33 drug candidates in clinical development, they are specialized in 5 major axes: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases and neuropsychiatric diseases.

In the field of immuno-inflammatory and auto-immune diseases, the company is eager to establish new contacts and mid-to-long term partnerships with financial support helping partners to transform innovative projects into patient benefit. Besides extensive research facilities, they also have full capabilities to conduct clinical studies and to help get a new product marketed. The partnerships with projects are flexible in the deal structure: joint development, in-licensing or asset purchase.

The first priorities are projects regarding Lupus, Sjögren´s Syndrome, Systemic Sclerosis or any autoimmune or chronic inflammatory disease with related mechanisms. The targets are Th1/Th17 downregulation, Treg upregulation, stimulation of resolution phase of inflammation, any innovative pathway in our targeted diseases. The therapeutic strategies promoted are peptides, antibodies, small molecules, gene therapy, cell therapy and such. Excluded are diagnostics technics (biomarkers), vaccines, services, e-health and medical device.

The projects can be from late exploratory target or pathway partly validated - with evidence from disease-relevant models to target to hit - to preclinical and clinical candidates. Projects from late exploratory (validated targets) to clinical phase II in the scope of resolution phase are included.
Technical Specification or Expertise Sought:
The company is looking for new assets for the extension of its portfolio in chronic inflammatory diseases with similar physiopathological mechanisms:
¿ Downregulation of Th1 and/or Th17 immune responses;
¿ Upregulation of regulatory responses;
¿ Stimulation of resolution phase.

The prerequisites for project validation are:
¿ Target rational (in vitro and/or in vivo);
¿ Evidence for translation to humans (target/pathway modulation under disease conditions and/or genetic);
¿ Evidence for target drug-ability and establishing of a robust compound testing flow-scheme;
¿ Rationale for differentiation to marketed drugs;
¿ Safety related to target/pathway modulation- Integrin extracellular ligands: collagen, elastin, polylysine, fibronectin, laminin, nidogens, osteopontin.

Partner sought

Type and Role of Partner Sought:
The French company is looking for academic or industrial partners. The size of the industrial partner is not important, it can be a startup or a mid-size company.

The company is open to establish mid-to-long term partnerships with financial support. The type of partnership sought can be joint development, in-licensing or asset purchase.

The therapeutic strategies promoted are peptides, antibodies, small molecules, gene therapy, cell therapy and such. Excluded are diagnostics technics (biomarkers), vaccines, services, e-health and medical device.

Client

Type and Size of Client:
Industry >500
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
French